Gaithersburg, Maryland (PRWEB) February 27, 2006 -–
America Pharma Source (Apharmas) today announced that it has introduced a novel in vitro cationic lipid transfection reagent, Cellipon293™, for $98.40/ml, only about 30% of cost comparing to major brand products. Cellipon 293™ is specifically developed for the delivery of DNA/RNA into HEK293 cells as well as a broad range of mammalian cells. This product is based on proprietary lipid technology and exhibits high transfection efficiency, low cytotoxicity, and the best quality/price ratio. The price advantage and simple protocol enable researchers to get satisfactory results easy, fast, and cost-effective, which is critical for low-budget laboratories and high-volume users.
Due to reduction of the federal research budgets and increase of labor & material costs, more and more research laboratories face pressure of experimental expenses. Many researchers have spent a lot of valuable time to seek better solutions at affordable price; however, this time-consuming process often end up with concern about product quality. To balance product quality and price becomes a hard decision. Apharmas realizes this market need and keeps working on new product development at low cost, Cellipon293™ is the result of its efforts.
“We hope Cellipon293™ could be the top choice for these low-budget laboratories and high volume users for transfecting HEK 293 cells as well as many mammalian cells. To provide high-quality products at affordable price always is our philosophy and practice, we are continuing to offer more innovative products to these customers,” said Dr. Frank F. Yu, CEO of America Pharma Source. “This product is very competitive with those brand products, in terms of efficiency, toxicity, and price. I’d like to shift.” A beta-tester at a small gene therapy company wrote in his report.
America Pharma Source (Apharmas) is a growing biopharma developer, manufacturer, and sourcing provider. It offers products and services to pharmaceutical and biotech companies, universities and non-profit organizations to accelerate their bioscience research and drug development efforts. Apharmas develops new technologies and products on drug delivery system and discover new balanced therapy from natural sources. Founded in 2000, Apharmas has expanded its presence in world market and established a R&D and manufacture facility in China. For more information about Apharmas, visit the company’s web site at http://www.apharmas.com.
America Pharma Source
This press release may contain certain forward-looking statements regarding Apharmas's performance, including future products, or strategies or development that Apharmas expects to occur or anticipates occurring in the future. Such statements are based upon current expectations that involve a number of business risks and uncertainties. Such uncertainties and risks include, but are not limited to, risks associated with management of growth, competition, technology, national and international operation, etc.
# # #